CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge, and the underlying mechanisms are still poorly understood. In this study,...

Full description

Bibliographic Details
Main Authors: Jun Zhou, Kehao Le, Ming Xu, Jie Ming, Wen Yang, Qiulei Zhang, Linlin Lu, Zihan Xi, Shengnan Ruan, Tao Huang
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
breast cancer
tamoxifen resistance
CXCR4
AMD3100
AKT phosphorylation
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300887

Similar Items

Similar Items